The result from a clinical pilot study, in collaboration with the clinic of Oncology at the university hospitals in Lund and Malmö as well as the hospital in Kristianstad, shows that VibroSense Meter® and its technology can be used to predict the risk of getting permanent nerve damage caused by treatment of cancer with chemotherapy. The discovery is an important step to pave the way for a new biomarker that can support physicians within cancer treatment with chemotherapy.